Adjuvant nivolumab data published in NEJM show DFS benefit in bladder cancer
The published data are from the pivotal CheckMate 274 trial and are currently being reviewed by the FDA for a potential approval of nivolumab in this setting.
The published data are from the pivotal CheckMate 274 trial and are currently being reviewed by the FDA for a potential approval of nivolumab in this setting.
Neal D. Shore, MD, shares what he’s most looking forward to at this year’s American Urological Association Annual Meeting.
UroViu’s portable and versatile disposable cystoscopy platform delivers consistent performance, on par with reusable scopes, advancing clinical care, and limiting disposable waste. The benefit of…
“[This] shows a different approach for detecting circulating tumor DNA in bladder cancer patients, and it opens up the possibility for other biorepositories that have…
Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year
The test, which was launched in Canada in September 2023, is available through Nanostics’ accredited laboratory in Edmonton, Alberta.
“We felt that it was important to again address this topic because we have received numerous questions regarding the correct use of this code and…
“Results from these trials show that giving physicians an alert informing them of their patient’s actual risk for antibiotic resistance can help them choose the…
“Ultimately, we found that in this retrospective evaluation, there was no significant difference in recurrence-free survival in those who are treated with gemcitabine and docetaxel…
All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study…
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.